This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tanaka, M. Articles by Sato, K. Search for Related Content PubMed PubMed Citation Articles by Tanaka, M. Articles by Sato, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2002, p. 904-908, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.904-908.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vitro Antibacterial Activities of DQ-113, a Potent Quinolone, against Clinical Isolates

New Product Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan

Received 2 July 2001/ Returned for modification 12 September 2001/ Accepted 24 November 2001

The antibacterial activity of DQ-113, formerly D61-1113, was compared with those of antibacterial agents currently available. MICs at which 90% of the isolates tested are inhibited (MIC₉₀s) of DQ-113 against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus and methicillin-susceptible and -resistant coagulase-negative staphylococci were 0.03, 0.008, 0.03, and 0.06 µg/ml, respectively. Moreover, DQ-113 showed the most potent activity against ofloxacin-resistant and methicillin-resistant S. aureus, with a MIC₉₀ of 0.25µg/ml. DQ-113 inhibited the growth of all strains of Streptococcus pneumoniae, including penicillin-resistant strains, and Streptococcus pyogenes at 0.06 µg/ml, and DQ-113 was more active than the other quinolones tested against Enterococcus faecalis and Enterococcus faecium with MIC90s of 0.25 and 2 µg/ml, respectively. Against vancomycin-resistant enterococci, DQ-113 showed the highest activity among the reference compounds, with a MIC range from 0.25 to 2 µg/ml. DQ-113 also showed a potent activity against Haemophilus influenzae, including ampicillin-resistant strains (MIC90, 0.015 µg/ml), and Moraxella catarrhalis (MIC90, 0.03 µg/ml). The activity of DQ-113 was roughly comparable to that of levofloxacin against all species of Enterobacteriaceae. The MICs of DQ-113 against ofloxacin-susceptible Pseudomonas aeruginosa ranged from 0.25 to 2 µg/ml, which were four times higher than those of ciprofloxacin. From these results, DQ-113 showed the most potent activity against gram-positive pathogens among antibacterial agents tested.

This article has been cited by other articles:

• Hong, S. G., Moland, E. S., Wickman, P. A., Black, J. A., Hossain, A., Hanson, N. D., Thomson, K. S. (2007). In Vitro Studies with DQ-113 and Comparison Fluoroquinolones To Determine Propensities To Select Resistance in Gram-Positive Cocci. Antimicrob. Agents Chemother. 51: 1512-1514 [Abstract] [Full Text]  
• Kaneko, Y., Yanagihara, K., Miyazaki, Y., Tsukamoto, K., Hirakata, Y., Tomono, K., Kadota, J.-i., Tashiro, T., Murata, I., Kohno, S. (2003). Effects of DQ-113, a New Quinolone, against Methicillin- and Vancomycin-Resistant Staphylococcus aureus-Caused Hematogenous Pulmonary Infections in Mice. Antimicrob. Agents Chemother. 47: 3694-3698 [Abstract] [Full Text]  
• Otsu, Y., Yanagihara, K., Fukuda, Y., Miyazaki, Y., Tsukamoto, K., Hirakata, Y., Tomono, K., Kadota, J.-i., Tashiro, T., Murata, I., Kohno, S. (2003). In Vivo Efficacy of a New Quinolone, DQ-113, against Streptococcus pneumoniae in a Mouse Model. Antimicrob. Agents Chemother. 47: 3699-3703 [Abstract] [Full Text]  
• Zeitlinger, M. A., Dehghanyar, P., Mayer, B. X., Schenk, B. S., Neckel, U., Heinz, G., Georgopoulos, A., Muller, M., Joukhadar, C. (2003). Relevance of Soft-Tissue Penetration by Levofloxacin for Target Site Bacterial Killing in Patients with Sepsis. Antimicrob. Agents Chemother. 47: 3548-3553 [Abstract] [Full Text]